Browse
Claims
Search the graph by meaning. Each result carries its current verdict; open one to see its decomposition, provenance, and the reasoning behind the assessment.
ShowingImportancePrizesTopicStatin therapy
Statin (HMG-CoA reductase inhibitor) treatment: its lipid-lowering efficacy, pleiotropic effects, safety, and effects on clinical outcomes in randomized trials and practice. Not for non-statin lipid-lowering agents such as ezetimibe or PCSK9 inhibitors unless compared with statins.
Mendelian randomization estimates roughly threefold greater cardiovascular risk reduction per mmol/L lower LDL than statin randomized trials
VerifiedThe claim traces to reliable primary sources through a clear chain of evidence.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Mendelian randomizationLDL cholesterolAtherosclerotic cardiovascular diseaseimportance · minorImportance 0.35, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
Mendelian randomization and statin-trial estimates of LDL's cardiovascular effect are mutually consistent once duration of exposure is accounted for
VerifiedThe claim traces to reliable primary sources through a clear chain of evidence.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →LDL cholesterolMendelian randomizationAtherosclerotic cardiovascular diseaseimportance · minorImportance 0.35, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
Randomized trials show PCSK9 inhibitors added to statin therapy reduce major cardiovascular events
VerifiedThe claim traces to reliable primary sources through a clear chain of evidence.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →PCSK9 inhibitorsAtherosclerotic cardiovascular diseaseimportance · minorImportance 0.35, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
PCSK9 inhibitors reduce cardiovascular events in statin-treated patients
VerifiedThe claim traces to reliable primary sources through a clear chain of evidence.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →PCSK9 inhibitorsAtherosclerotic cardiovascular diseaseimportance · minorImportance 0.40, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
Statin randomized trials reduce major vascular events by about a fifth per 1 mmol/L reduction in LDL cholesterol
VerifiedThe claim traces to reliable primary sources through a clear chain of evidence.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Atherosclerotic cardiovascular diseaseLDL cholesterolimportance · minorImportance 0.40, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
Niacin added to statin therapy failed to reduce cardiovascular events
UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →NiacinAtherosclerotic cardiovascular diseaseimportance · minorImportance 0.25, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
Ezetimibe added to statin therapy further lowers LDL cholesterol
UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →EzetimibeLDL cholesterolimportance · settledImportance 0.15, from 0 to 1 · settled: uncontested, so low even when much depends on it. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
Contribute
If a claim here is wrong, or missing evidence, open it: every claim page carries its own entry for challenges, evidence, and corrections. If the graph is missing a claim entirely, propose it below. A proposal is reviewed on its merits; accepted claims are matched against the graph and enter it with their reasoning on record.